GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO.B) » Definitions » Capex-to-Revenue

Bio-Rad Laboratories (Bio-Rad Laboratories) Capex-to-Revenue : 0.06 (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Bio-Rad Laboratories Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Bio-Rad Laboratories's Capital Expenditure for the three months ended in Dec. 2023 was $-42.25 Mil. Its Revenue for the three months ended in Dec. 2023 was $681.18 Mil.

Hence, Bio-Rad Laboratories's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.06.


Bio-Rad Laboratories Capex-to-Revenue Historical Data

The historical data trend for Bio-Rad Laboratories's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Capex-to-Revenue Chart

Bio-Rad Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.04 0.05 0.04 0.06

Bio-Rad Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.05 0.07 0.06

Competitive Comparison of Bio-Rad Laboratories's Capex-to-Revenue

For the Medical Devices subindustry, Bio-Rad Laboratories's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Rad Laboratories's Capex-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Capex-to-Revenue falls into.



Bio-Rad Laboratories Capex-to-Revenue Calculation

Bio-Rad Laboratories's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-156.68) / 2671.262
=0.06

Bio-Rad Laboratories's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-42.245) / 681.184
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Rad Laboratories  (NYSE:BIO.B) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Bio-Rad Laboratories Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Traded in Other Exchanges
Address
1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Bio-Rad Laboratories (Bio-Rad Laboratories) Headlines